Telangana has attracted investments totaling ₹36,000 crore in the life sciences sector since the Congress government took office in December last year, according to Industries Minister Sridhar Babu. Speaking to the media on Thursday, Babu highlighted that the state has seen a significant surge in both international and domestic investments, with more than 140 projects contributing to the growth of Telangana's life sciences ecosystem.
These investments have led to the creation of 51,000 direct jobs, with an additional 1,50,000 indirect jobs expected to follow. Babu described Telangana as an "undisputed leader" in the global life sciences space, noting the substantial contributions to pharmaceutical manufacturing, research and development (R&D) centers, and innovation hubs.
In the past year alone, European firms KrKA and Laurus Labs committed a combined ₹2,000 crore to Genome Valley, a key cluster for pharmaceutical production and biopharmaceutical manufacturing. Laurus Labs also set up an advanced R&D center with an investment of ₹250 crore, creating a potential 2,800 jobs.
Japanese pharmaceutical giant Takeda entered into a partnership with Biological E Ltd. to produce 5 crore doses of a dengue vaccine annually in Genome Valley, reinforcing Hyderabad’s status as the "vaccine capital of the world."
The state has also attracted investments from Rx Propellant and Terminus Group, which are putting ₹2,000 crore into the development of world-class lab spaces and R&D infrastructure, generating up to 10,000 new jobs. Additionally, collaborations with Thermo Fisher have led to the establishment of the country’s first scale-up biological manufacturing facility and bioprocess design center in Genome Valley.
Germany’s Miltenyi Biotec is setting up a state-of-the-art cell and gene therapy facility, while Aragen, a leading CRO/CDMO, is expanding its operations in Nacharam with a ₹2,000 crore investment that will create 1,000 new jobs.
Minister Babu also shared that the Telangana government plans to introduce a dedicated life sciences policy aimed at further streamlining investment processes, fostering innovation, and ensuring the state's continued growth in the global life sciences value chain.
HBL
This site is best viewed with a resolution of 1024x768 (or higher) and supports Microsoft Internet Explorer 4.0 (or higher)
Copyright © 2016-2026

